Analyst Ratings for [CRSP] CRISPR Therapeutics AG

2/14/25	Upgrades	In-line Outperform	X
CRSP CRISPR Therapeutics Evercore ISI
$60 $99
2/12/25	Upgrades	Sell Hold	X
CRSP CRISPR Therapeutics TD Cowen
$35
2/3/25	Initiated	Buy	X
CRSP CRISPR Therapeutics H.C. Wainwright
$65
8/6/24	Reiterated	Buy	X
CRSP CRISPR Therapeutics Needham
$88 $84
6/28/24	Resumed	Neutral	X
CRSP CRISPR Therapeutics Guggenheim
2/15/24	Initiated	Peer Perform	X
CRSP CRISPR Therapeutics Wolfe Research
12/11/23	Downgrades	Mkt Perform Underperform	X
CRSP CRISPR Therapeutics TD Cowen
$30
9/27/23	Initiated	Buy	X
CRSP CRISPR Therapeutics Mizuho
$82
8/17/23	Upgrades	Neutral Buy	X
CRSP CRISPR Therapeutics Citigroup
5/30/23	Initiated	Outperform	X
CRSP CRISPR Therapeutics William Blair
$75
4/13/23	Initiated	Overweight	X
CRSP CRISPR Therapeutics Cantor Fitzgerald
$72
3/21/23	Initiated	Mkt Perform	X
CRSP CRISPR Therapeutics Bernstein
$44
3/17/23	Initiated	Buy	X
CRSP CRISPR Therapeutics Bryan Garnier
$70
3/7/23	Initiated	Neutral	X
CRSP CRISPR Therapeutics Robert W. Baird
$46
10/11/22	Initiated	Underweight	X
CRSP CRISPR Therapeutics Morgan Stanley
$37
8/9/22	Downgrades	Overweight Eq Weight	X
CRSP CRISPR Therapeutics Barclays
$99 $88
6/23/22	Downgrades	Outperform In-line	X
CRSP CRISPR Therapeutics Evercore ISI
$66 $60
6/17/22	Initiated	Outperform	X
CRSP CRISPR Therapeutics BMO Capital Markets
$98
4/28/22	Initiated	Neutral	X
CRSP CRISPR Therapeutics Credit Suisse
$78
12/7/21	Initiated	Market Perform	X
CRSP CRISPR Therapeutics Cowen
10/19/21	Initiated	Outperform	X
CRSP CRISPR Therapeutics SVB Leerink
$126
6/14/21	Upgrades	Sell Neutral	X
CRSP CRISPR Therapeutics Citigroup
$55 $132
4/21/21	Upgrades	Hold Buy	X
CRSP CRISPR Therapeutics Jefferies
$172
3/4/21	Initiated	Mkt Outperform	X
CRSP CRISPR Therapeutics JMP Securities
$160
8/1/19	Initiated	Buy	X
CRSP CRISPR Therapeutics Jefferies
$64
7/26/19	Initiated	Buy	X
CRSP CRISPR Therapeutics Canaccord Genuity
$72
6/10/19	Initiated	Buy	X
CRSP CRISPR Therapeutics ROTH Capital
$50
4/12/19	Initiated	Outperform	X
CRSP CRISPR Therapeutics Evercore ISI
3/14/19	Initiated	Mkt Perform	X
CRSP CRISPR Therapeutics William Blair
1/28/19	Downgrades	Buy Neutral	X
CRSP CRISPR Therapeutics Goldman
1/22/19	Downgrades	Neutral Sell	X
CRSP CRISPR Therapeutics Citigroup
11/30/18	Initiated	Buy	X
CRSP CRISPR Therapeutics Needham
$62
10/10/18	Initiated	Neutral	X
CRSP CRISPR Therapeutics Guggenheim
10/10/18	Initiated	Outperform	X
CRSP CRISPR Therapeutics Wells Fargo
$65
9/21/18	Initiated	Underperform	X
CRSP CRISPR Therapeutics Raymond James
5/15/18	Reiterated	Buy	X
CRSP CRISPR Therapeutics Chardan Capital Markets
$25 $72.50
4/6/18	Initiated	Buy	X
CRSP CRISPR Therapeutics Goldman
$86
3/8/18	Initiated	Mkt Outperform	X
CRSP CRISPR Therapeutics JMP Securities
$69

CRSP CRISPR Therapeutics AG

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.